Q&A with Erik van den Berg, AM-Pharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Erik van den Berg, AM-Pharma
A Q&A with Erik van den Berg, CEO of AM-Pharma, on recent industry trends.

Pharmaceutical Technology
Volume 36, Issue 4, pp. 144

PharmTech:
How has the increasing focus on biopharmaceuticals affected your business?



Van den Berg:
AM-Pharma is solely focused on biopharmaceuticals. We have established proof-of-concept data with bovine alkaline phosphatase in the treatment of acute kidney injury. Now, we will manufacture recombinant human alkaline phosphatase and perform subsequent clinical studies with this recombinant material.

PharmTech:
How will the industry remain innovative as it reduces spending on research?

Van den Berg:
The large pharmaceutical companies have become dependent on external R&D. More than 50% of the clinical pipeline is derived from small biotech or academia. The reduced spending on research should be supplemented with higher investment in development and acquisition/licensing expenses.

PharmTech:
Do you see a new industry trend emerging?

Van den Berg:
The industry trend is towards more and more outsourcing of development activities.

PharmTech:
How is your company responding to regulators' intensifying emphasis on inspections and product quality?

Van den Berg:
Our quality system is aligned with industry expectations, which means that collaborations are managed by quality agreements and involve regular inspections. In addition, we maintain contact with the regulatory authorities early on in the development program to include their requests and recommendations.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here